Bafna Pharmaceuticals's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Bafna Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:
NSE:BAFNAPH's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.205 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Bafna Pharmaceuticals 5-Year Yield-on-Cost % Related Terms
NSE:BAFNAPH vs ZTS, UTHR: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bafna Pharmaceuticals 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Bafna Pharmaceuticals's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Bafna Pharmaceuticals (NSE:BAFNAPH) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 12, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Bafna Pharmaceuticals and its competitors. According to the industry distribution chart, Bafna Pharmaceuticals ranks #999999 out of 516 companies in the Drug Manufacturers industry.
Is Bafna Pharmaceuticals' 5-Year Yield-on-Cost % too high?
Bafna Pharmaceuticals' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Bafna Pharmaceuticals ranks #999999 out of 516 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bafna Pharmaceuticals has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bafna Pharmaceuticals ranks #999999 out of 516 companies for 5-Year Yield-on-Cost %. This places Bafna Pharmaceuticals in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.21, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Bafna Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bafna Pharmaceuticals's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹90.92, compared to a current price of ₹204.61 — trading 125% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Bafna Pharmaceuticals' overall GF Score™ is 66/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?
Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹204.61 is trading 125% above its estimated GF Value™ of ₹90.92.
GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:BAFNAPH:
5-Year Yield-on-Cost %: 0.00
GF Value™: ₹90.92 vs. price of ₹204.61 (125% above fair value)
No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
66GF Score
Get the complete analysis for NSE:BAFNAPH
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BAFNAPH has been successfully added to your 